行情

QURE

QURE

Uniqure
NASDAQ

实时行情|Nasdaq Last Sale

42.01
+0.65
+1.57%
交易中 12:43 08/11 EDT
开盘
41.32
昨收
41.36
最高
42.07
最低
40.51
成交量
11.05万
成交额
--
52周最高
76.69
52周最低
36.20
市值
18.67亿
市盈率(TTM)
-13.4742
分时
5日
1月
3月
1年
5年

分析师评级

17位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测QURE价格均价为73.93,最高价位91.00,最低价为56.00。

EPS

QURE 新闻

更多
UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of -100.00% and -91.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 14:25
uniQure Q2 EPS $(0.96) Down From $(0.83) YoY
uniQure (NASDAQ:QURE) reported quarterly losses of $(0.96) per share. This is a 15.66 percent decrease over losses of $(0.83) per share from the same period last year.
Benzinga · 07/30 12:35
uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress
~ Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure’s Gene Therapy Candidate for Hemophilia B ~~ Completed First Patient Dosing in Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease ~LEX
GlobeNewswire · 07/30 11:05
A Quick Investment Idea On uniQure
Seeking Alpha · 07/30 04:00
uniQure EPS misses by $0.31, misses on revenue
Seeking Alpha · 07/30 04:00
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/27 16:31
Annexon Initiates $100 Million IPO Effort
Seeking Alpha - Article · 07/11 15:00
Were Hedge Funds Right About Piling Into Uniqure NV (QURE)?
Insider Monkey · 07/08 17:38

所属板块

生物技术和医学研究
-0.72%
制药与医学研究
+0.02%

热门股票

代码
价格
涨跌幅

QURE 简况

Uniqure NV是一家从事基因治疗业务的荷兰公司。它旨在为患有遗传性和其他破坏性疾病的患者开发一种单次疗法,以达到潜在的治疗效果。该公司通过内部和合作伙伴关系开发了一系列基因疗法。该公司在自有设施中以当前专有的具有商业规模的良好生产规范、合规的制造工艺来生产基于腺相关病毒或基于AAV的基因疗法。该公司针对B型血友病患者的主要候选药物AMT-061正在进行一项关键性研究的给药阶段。AMT-130是亨廷顿氏病患者的候选产品,目前正在进行I/II期临床研究。
展开

微牛提供Uniqure NV(NASDAQ-QURE)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的QURE股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易QURE股票基本功能。